<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-30T03:25:17Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/7559" metadataPrefix="edm">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/7559</identifier><datestamp>2023-04-18T12:48:15Z</datestamp><setSpec>com_10259_3924</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_3925</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xsi:schemaLocation="http://www.w3.org/1999/02/22-rdf-syntax-ns# http://www.europeana.eu/schemas/edm/EDM.xsd">
<edm:ProvidedCHO rdf:about="http://hdl.handle.net/10259/7559">
<dc:creator>Espona Fiedler, Margarita</dc:creator>
<dc:creator>Manuel Manresa, Pilar</dc:creator>
<dc:creator>Benítez-García, Cristina</dc:creator>
<dc:creator>Fontova Pale, Pere</dc:creator>
<dc:creator>Quesada Pato, Roberto</dc:creator>
<dc:creator>Soto Cerrato, Vanessa</dc:creator>
<dc:creator>Pérez Tomás, Ricardo</dc:creator>
<dc:date>2022-12</dc:date>
<dc:description>Metastasis is the primary cause of death in cancer patients. Many current chemotherapeutic&#xd;
agents only show cytotoxic, but not antimetastatic properties. This leads to a reduction in tumor&#xd;
size, but allows cancer cells to disseminate, which ultimately causes patient death. Therefore, novel&#xd;
anticancer compounds with both effects need to be developed. In this work, we analyze the antimetastatic properties of prodigiosin and obatoclax (GX15-070), anticancer drugs of the Prodiginines&#xd;
(PGs) family. We studied PGs’ effects on cellular adhesion and morphology in the human primary&#xd;
and metastatic melanoma cell lines, SK-MEL-28 and SK-MEL-5, and in the murine melanoma cell&#xd;
line, B16F10A. Cell adhesion sharply decreased in the treated cells, and this was accompanied by a&#xd;
reduction in filopodia protrusions and a significant decrease in the number of focal-adhesion structures. Moreover, cell migration was assessed through the wound-healing assay and cell motility was&#xd;
severely inhibited after 24 h of treatment. To elucidate the molecular mechanisms involved, changes&#xd;
in metastasis-related genes were analyzed through a gene-expression array. Key genes related to&#xd;
cellular invasion, migration and chemoresistance were significantly down-regulated. Finally, an&#xd;
in vivo model of melanoma-induced lung metastasis was established and significant differences in&#xd;
lung tumors were observed in the obatoclax-treated mice. Altogether, these results describe, in depth,&#xd;
PGs’ cellular antimetastatic effects and identify in vivo antimetastatic properties of Obatoclax.</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>http://hdl.handle.net/10259/7559</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>MDPI</dc:publisher>
<dc:title>Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma</dc:title>
<dc:type>info:eu-repo/semantics/article</dc:type>
<edm:type>TEXT</edm:type>
</edm:ProvidedCHO>
<ore:Aggregation rdf:about="http://hdl.handle.net/10259/7559#aggregation">
<edm:aggregatedCHO rdf:resource="http://hdl.handle.net/10259/7559"/>
<edm:dataProvider>RIUBU. Repositorio Institucional de la Universidad de Burgos</edm:dataProvider>
<edm:isShownAt rdf:resource="http://hdl.handle.net/10259/7559"/>
<edm:isShownBy rdf:resource="https://riubu.ubu.es/bitstream/10259/7559/1/Espona-pharmaceutics_2022.pdf"/>
<edm:object rdf:resource="https://riubu.ubu.es/bitstream/10259/7559/4/Espona-pharmaceutics_2022.pdf.jpg"/>
<edm:provider>Hispana</edm:provider>
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</ore:Aggregation>
<edm:WebResource rdf:about="https://riubu.ubu.es/bitstream/10259/7559/1/Espona-pharmaceutics_2022.pdf">
<edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
</edm:WebResource>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>